4.1. General metabolic considerations for patient work-up

4.1.1. Evaluation of patient risk

After stone passage, every patient should be assigned to a low- or high-risk group for stone formation (Figure 4.1). For correct classification, two items are mandatory:

  • reliable stone analysis by infrared spectroscopy or X-ray diffraction;
  • basic analysis (Section 3.3.2).

Only high-risk stone formers require specific metabolic evaluation. Stone type is the deciding factor for further diagnostic tests. The different stone types include:

  • calcium oxalate;
  • calcium phosphate;
  • uric acid;
  • ammonium urate;
  • struvite (and infection stones);
  • cystine;
  • xanthine;
  • 2,8-Dihydroxyadenine;
  • drug stones;
  • stones of unknown composition.

Figure 4.1: Assignment of patients to low- or high-risk groups for stone formation

4.1.2. Urine sampling

Specific metabolic evaluation requires collection of two consecutive 24-hour urine samples [69,578,579]. The collecting bottles should be prepared 1 g thymol per litre in or stored at < 8°C during collection to reduce bacterial proliferation [69]. Pre-analytical errors can be minimised by carrying out urinalysis immediately after collection. Alternatively, boric acid (10 g powder per urine container) can also be used, but this prevents the correct determination of pH [69]. The collecting method should be chosen in close cooperation with the laboratory. A pH < 5.5 in a 24-hour urine indicates hyper acidic urine (acidic arrest) [580-582]. During therapy urine pH should be assessed during collection of freshly voided urine at different times throughout the day using sensitive pH-dipsticks or a pH-meter [27,69,583]. A urine pH on 24-hr collection > 6.2 is suspicious for distal RTA [584]. A consensus statement from Gambaro et al., stated that RTA is suspected if 24-hr urine pH is > 6.2 and fasting second morning spot urine pH is > 5.8 [585].

Spot urine samples are an alternative method of sampling, particularly when 24-hour’s urine collection is difficult, for example, in non-toilet trained children [586]. Spot urine studies normally link the excretion rates to creatinine [587], but these are of limited use because the results may vary with collection time and patients’ sex, body weight and age.

4.1.3. Timing of specific metabolic work-up

For the initial specific metabolic work-up, the patient should stay on a self-determined diet under normal daily conditions and should ideally be stone free for at least twenty days [588]. Follow-up studies are necessary in patients taking medication for recurrence prevention [589]. The first follow-up 24-hour urine measurement is suggested eight to twelve weeks after starting pharmacological prevention of stone recurrence. This enables drug dosage to be adjusted if urinary risk factors have not normalised, with further 24-hour urine measurements, if necessary. Once urinary parameters have been normalised, it is sufficient to perform 24-hour urine evaluation every twelve months. On this issue the Panel realise that there is only very limited published evidence.

4.1.4. Reference ranges of laboratory values

Tables 4.1-4.4 provide the internationally accepted reference ranges for the different laboratory values in serum and urine.

Table 4.1: Normal laboratory values for blood parameters in adults [27,589]

Blood parameter

Reference range


50-100 μmol/L


135-145 mmol/L


3.5-5.5 mmol/L


2.0-2.5 mmol/L (total calcium)

1.12-1.32 mmol/L (ionised calcium)

Uric acid

119-380 μmol/L


98-112 mmol/L


0.81-1.29 mmol/L

Blood gas analysis




80-90 mmHg


35-45 mmHg


22-26 mmol/L


BE ± 2 mmol/L

BE = base excess (loss of buffer base to neutralise acid); HCO3 = bicarbonate; pCO2 = partial pressure ofcarbon dioxide; pO2 = partial pressure of oxygen.

4.1.5. Risk indices and additional diagnostic tools

Several risk indices have been developed to describe the crystallisation risk for calcium oxalate or calcium phosphate in urine [590-593]. However, clinical validation of these risk indices for recurrence prediction or therapy improvement is ongoing.

Table 4.2: Laboratory values for urinary parameters in adults

Urinary Parameters

Reference ranges and limits for medical attention


Consistently fasting morning spot urine pH > 5.8 and > 6.2 in 24-hr collection (suspicious of renal tubular acidosis) [584,585]

Consistently > 7.0 (suspicious of infection)

Consistently < 5.5 in morning urine and in 24-hr collection (suspicious of acidic arrest) [580,594]

Specific weight

Specific weight > 1.010


7-13 mmol/day (females), 13-18 mmol/day (males)


> 5.0 mmol/day (see Fig. 4.2)

> 8.0 mmol/day (see Fig. 4.2)


> 0.5 mmol/day (suspicious of enteric hyperoxaluria)

>1.0 mmol/day (suspicious of primary hyperoxaluria)

Uric acid

> 4.0 mmol/day (females), 5 mmol/day (males)


< male < 1.7 mmol/day, female < 1.9 mmol/day


< 3.0 mmol/day

Inorganic phosphate

> 35 mmol/day


> 50 mmol/day


> 0.8 mmol/day

Table 4.3: Normal values for spot urine samples: creatinine ratios (solute/creatinine) in children [595]

Parameter/Patient age

Ratio of solute to creatinine





< 12 months

< 2.0


1-3 years

< 1.5


1-5 years

< 1.1


5-7 years

< 0.8


> 7 years

< 0.6





0-6 months

< 325-360


7-24 months

< 132-174


2-5 years

< 98-101


5-14 years

< 70-82


> 16 years

< 40





0-5 years

> 0.25


> 5 years

> 0.15





All age groups

> 0.63

> 0.13

Uric acid

> 2 years

< 0.56 mg/dL (33 μmol/L) per GFR (ratio x plasma creatinine)

* There is low-level evidence regarding the importance of magnesium.

Table 4.4: Solute excretion in 24-hour urine samples in children *

Calcium/24 hour

Citrate/24 hour

Cystine/24 hour

Oxalate/24 hour

Urate/24 hour

All age groups



< 10 years

> 10 years

All age groups

< 1 year

1-5 years

> 5 years

< 0.1 mmol/kg/

24 h

> 1.9 mmol/ 1.73 m2/24 h

> 1.6 mmol/ 1.73 m2/24 h

< 55 μmol/

1.73 m2/24 h

< 200 μmol/

1.73 m2/24 h

< 0.5 mmol/

1.73 m2/24 h

< 70 μmol/kg/24 h

< 65 mμmol/kg/24 h

< 55 μmol/kg/24 h

< 4 mg/kg/24 h

> 365 mg/

1.73 m2/24 h

> 310 mg/

1.73 m2/24 h

< 13 mg/

1.73 m2/24 h

< 48 mg/

1.73 m2/24 h

< 45 mg /

1.73 m2/24 h

< 13 mg/

kg/24 h

< 11 mg/

kg/24 h

< 9.3 mg/kg/24 h

* 24 h urine parameters are diet and gender dependent and may vary geographically.

4.2. General considerations for recurrence prevention

All stone formers, independent of their individual risk, should follow the preventive measures in Table 4.5. The main focus is normalisation of dietary habits and lifestyle risks. Stone formers at high risk need specific prophylaxis for recurrence, which is usually pharmacological treatment based on stone analysis and urinary risk profile.

Table 4.5: General preventive measures

Fluid intake (drinking advice)

Fluid amount: 2.5-3.0 L/day

Fluid amount: 2.5-3.0 L/day

Water is the preferred fluid

Diuresis: 2.0-2.5 L/day

Specific weight of urine: < 1,010 g/day

Nutritional advice for a balanced diet

Balanced diet*

Rich in vegetables and fibre

Normal calcium content: 1-1.2 g/day

Limited NaCl content: 4-5 g/day

Limited animal protein content: 0.8-1.0 g/kg/day

Lifestyle advice to normalise general risk factors

BMI: Retain a normal BMI level

Adequate physical activity

Balancing of excessive fluid loss

Reduce the intake of alcohol containing fluids

Reduce the intake of sodas and calorie-containing fluids

Caution: Protein requirements are age dependent; therefore, protein restriction in childhood should be handled carefully.
* Avoid excessive consumption of vitamin supplements.

4.2.1. Fluid intake

An inverse relationship between high fluid intake and stone formation has been repeatedly demonstrated [596-600]. The beneficial effect of fruit juices is mainly determined by the presence of citrate or bicarbonate [601]. Citrus fruit juices seem to protect against stone disease either by increasing urinary citrate levels or by having an alkalinising effect on it [602]. However, if potassium is present, both pH and citrate are increased [603,604]. One large moderate quality RCT randomly assigned men with more than one past renal stone of any type and soft drink consumption of at least 160 mL/day to reduced soft drink intake or no treatment. Although the intervention significantly reduced the risk for symptomatic recurrent stones (RR: 0.83; CI: 0.71-0.98), the level of evidence for this outcome is low because results were from only one trial [605]. An analysis on the 3 Channing’s cohorts (194,095 participants) over a median follow-up of more than eight years has shown that consumption of sugar-sweetened soda and punch is associated with a higher risk of stone formation, whereas consumption of coffee, tea, beer, wine, and orange juice is associated with a lower risk [606], whereas consumption of tea and coffee does not seem to increase the risk of stones disease [607]. However, the intake of fluids should be considered within a holistic approach to health. Some of them contain calories or alcohol that may be detrimental to health. Therefore, water should be the preferred fluid.

4.2.2. Diet

A common-sense approach to diet should be taken, that is, a mixed, balanced diet with contributions from all food groups, without any excesses [597,608,609]. Sufficient calcium intake is needed, especially in vegetarian and vegan diets [610].

Fruit, vegetables and fibre: Fruit and vegetable intake should be encouraged because of the beneficial effects of fibre, although the role of the latter in preventing stone recurrences is debatable [611-614]. The alkaline content of a vegetarian diet also increases urinary pH. In addition, fruit and vegetables have a high water content and can significantly contribute to fluid intake.

Oxalate: Excessive intake of oxalate-rich products should be limited or avoided to prevent high oxalate load [615], particularly in patients who have high oxalate excretion.

Vitamin C: Although vitamin C is a precursor of oxalate, its role as a risk factor in calcium oxalate stone formation remains controversial [616]. However, it seems wise to advise calcium oxalate stone formers to avoid excessive intake.

Animal protein: Animal protein should not be consumed in excess [617,618] and limited to 0.8-1.0 g/kg body weight. Excessive consumption of animal protein has several effects that favour stone formation, including hypocitraturia, low urine pH, hyperoxaluria and hyperuricosuria.

Calcium intake: Calcium should not be restricted, unless there are strong reasons for doing so, due to the inverse relationship between dietary calcium and stone formation [612,619]. The daily requirement for calcium is 1,000 to 1,200 mg [27]. Calcium supplements are not recommended except in enteric hyperoxaluria, when additional calcium should be taken with meals to bind intestinal oxalate [597,615,617,620]. Older adults who do not have a history of renal stones but who take calcium supplements should ensure adequate fluid intake since it may prevent increases in urine calcium concentration, and thereby reduce or eliminate any increased risk of renal stones formation associated with calcium supplement use [621].

Sodium: Daily sodium (NaCl) intake should not exceed 3-5 g [27]. High intake adversely affects urine


  • calcium excretion is increased by reduced tubular re-absorption;
  • urinary citrate is reduced due to loss of bicarbonate;
  • increased risk of sodium urate crystal formation.

Calcium stone formation can be reduced by restricting sodium and animal protein [617,618]. A positive correlation between sodium consumption and risk of first-time stone formation has been confirmed only in women [619]. There have been no prospective clinical trials on the role of sodium restriction as an independent variable in reducing the risk of stone formation.

Urate: Intake of purine-rich food should be restricted in patients with hyperuricosuric calcium oxalate [622,623] and uric acid stones. Intake should not exceed 500 mg/day [27].

4.2.3. Lifestyle

Lifestyle factors may influence the risk of stone formation, for example, those causing obesity [624], diabetes mellitus [625], and metabolic syndrome [626].

4.2.4. Summary of evidence and recommendation for recurrence prevention

Summary of evidence


Increasing water intake reduces the risk of stone recurrence.



Strength rating

Advise patients that a generous fluid intake is to be maintained, allowing for a 24-hour urine volume > 2.5 L.


4.3. Stone-specific metabolic evaluation and pharmacological recurrence prevention

4.3.1. Introduction

Pharmacological treatment is necessary in patients at high risk for stone formation or for associated systemic conditions. The ideal drug should halt stone formation, have no side effects, and be easy to administer. Each of these aspects is important to achieve good compliance. Table 4.6 highlights the most important characteristics of commonly used medication.

Table 4.6: Pharmacological substances used for stone prevention - characteristics, specifics and dosage




Specifics and side effects

Stone type


Alkaline citrates



Inhibition of calcium oxalate crystallisation

5-12 g/d

(14-36 mmol/d)


0.1-0.15 g/kg/d

Daily dose for alkalinisation depends on urine pH.

Calcium oxalate

Uric acid






100-300 mg/d


1-3 mg/kg/d

100 mg in isolated


Renal insufficiency

demands dose


Contraindicated in acute gout, pregnancy, and breastfeeding.

Allergies from trivial to very severe forms, xanthine stone formation.

Calcium oxalate

Uric acid

Ammonium urate




Enteric hyperoxaluria

Up to 2,000 mg/d depending on oxalate excretion

Intake 30 min before meals.

Calcium oxalate




Active decrease of urinary cystine levels

75-150 mg

Second-line option in case of significant side effects of tiopronin.






80-120 mg/d

Contraindicated in acute gout, pregnancy and breastfeeding.

Xanthine stone formation.

Calcium oxalate

Uric acid

[640, 641



600-1,500 mg/d

Hypercalciuria, bone demineralisation, systemic acidosis.

No long-term therapy.

Infection stones

Ammonium urate

Calcium phosphate



Isolated hypomagnesiuria

Enteric hyperoxaluria

200-400 mg/d


6 mg/kg/d

Renal insufficiency demands dose correction.

Diarrhoea, chronic alkali losses, hypocitraturia.

Calcium oxalate


(Low level of


Sodium bicarbonate



4.5 g/d


Calcium oxalate

Uric acid, Cystine





Initial dose

5 mg/kg/d

Max. 20 mg/kg/d

Sensory peripheral neuropathy.

Calcium oxalate


Thiazide (Hydrochlorothiazide*)


25-50 mg/d


0.5-1 mg/kg/d

Risk for hypotonic

blood pressure,

diabetes, hyperuricaemia,


followed by

intracellular acidosis and hypocitraturia.

Calcium oxalate

Calcium phosphate




Active decrease of urinary cystine levels

Initial dose

800 mg/d

Avg. 2,000 mg/d**


Initial dose in patients > 20kg is 15 mg/kg/day.

Avoid dosages
> 50mg/kg/day

Risk for tachyphylaxis and proteinuria.



* Patients on hydrochlorothiazides should be advised to get their skin checked on a regular basis as they have a higher risk of developing a non-melanoma skin cancer (NMSC) and some forms of melanoma. In patients with history of skin cancer the indication for the intake of hydrochlorothiazides should be thoroughly reviewed 661-663.
** No information is available on maximum dose and patients may be initiated on a very low dose if they have had previously had reactions to tiopronin or penicillamine. For all patients, dosage should be titrated according to frequency of stone episodes, side effects and renal function under expert supervision with close monitoring.

4.4. Calcium oxalate stones

The criteria for identification of calcium oxalate stone formers with high recurrence risk are listed in section 3.1.3.

4.4.1. Diagnosis

Blood analysis requires measurement of creatinine, sodium, potassium, chloride, ionised calcium (or total calcium + albumin), phosphate, uric acid; and, in the case of increased calcium levels, parathyroid hormone (PTH) and vitamin D. Urinalysis requires measurement of urine volume, urine pH profile, specific weight, calcium, oxalate, uric acid, citrate, sodium and magnesium. Figure 4.2 summarises the diagnostic steps for calcium oxalate stones.

Figure 4.2: Diagnostic algorithm for calcium oxalate stones

4.4.2. Interpretation of results and aetiology

The most common metabolic abnormalities associated with calcium stone formation are hypercalciuria, which affects 30-60% of adult stone formers, and hyperoxaluria (26-67%), followed by hyperuricosuria (15-46%), hypomagnesuria (7-23%), and hypocitraturia (5-29%). However, ranges tend to differ based on ethnicity [664].

  • Elevated levels of ionised calcium in serum (or total calcium and albumin) require assessment of intact PTH to confirm or exclude suspected hyperparathyroidism (HPT).
  • Consistently low pH (< 5.5) or 24-hr urine pH < 5.5 may promote co-crystallisation of uric acid and calcium oxalate.
  • Similarly, increased uric acid excretion (> 4 mmol/day in adults or > 12 mg/kg/day in children) can act as a promoter.
  • A pH > 6.2 in a 24-hr urine collection may indicate RTA provided UTI has been excluded. An ammonium chloride loading test confirms RTA and identifies RTA subtype (Section 4.6.5).
  • Hypercalciuria may be associated with normocalcemia (idiopathic hypercalciuria, or granulomatous diseases) or hypercalcaemia (hyperparathyroidism, granulomatous diseases, vitamin D excess, or malignancy).
  • Hypocitraturia (male < 1.7 mmol/d, female < 1.9 mmol/d) may be idiopathic or secondary to metabolic acidosis or hypokalaemia.
  • Oxalate excretion > 0.5 mmol/day in adults confirms hyperoxaluria (see Table 4.3 for the values in children): primary hyperoxaluria (oxalate excretion mostly > 1 mmol/day), appears in three genetically determined forms; secondary hyperoxaluria (oxalate excretion > 0.5 mmol/day, usually < 1 mmol/day), occurs due to intestinal hyperabsorption of oxalate or extreme dietary oxalate intake; and mild hyperoxaluria (oxalate excretion 0.45-0.85 mmol/day), commonly found in idiopathic calcium oxalate stone formers.
  • Hypomagnesuria (< 3.0 mmol/day) may be related to poor dietary intake or to reduced intestinal absorption (chronic diarrhoea).

Figure 4.3: Therapeutic algorithm for calcium oxalate stones1 Be aware of excess calcium excretion.
2 tid = three times/day (24h).
3 No magnesium therapy for patients with renal insufficiency.
4 There is no evidence that combination therapy (thiazide + citrate) or (thiazide + allopurinol) is superior to thiazide therapy alone [628].
5 Febuxostat 80 mg/day.* low evidence (see text)
** Calciuria is a continuous variable and treatment may be adjusted to clinical need even when below the threshold indicated.
***Patients on hydrochlorothiazides should be advised to get their skin checked on a regular basis as they have a higher risk of developing a NMSC and some forms of melanoma. In patients with history of skin cancer the indication for the intake of hydrochlorothiazides should be thoroughly reviewed [661-663].

4.4.3. Specific treatment

General preventive measures are recommended for fluid intake and diet. Hyperoxaluric stone formers should consume foods with low oxalate content, whereas hyperuricosuric stone formers benefit from daily dietary reduction of purine. Figure 4.3 summarises the pharmacological treatment of calcium oxalate stones [597,604,627-630,633,634,636,640,643-645,649-656,664,666-669]. There is only low-level evidence for the efficacy of preventing stone recurrence based on pre-treatment stone composition examination and biochemistry measures, or on-treatment biochemistry measures [597].

4.4.4. Summary of evidence and recommendations for pharmacological treatments for patients with specific abnormalities in urine composition (based on 24-hour urine samples)

Summary of evidence


Thiazide or alkaline citrates or both can reduce stone formation.


Oxalate restriction is beneficial if hyperoxaluria is present.


Alkaline citrates can reduce stone formation in enteric hyperoxaluria.


Calcium supplement can reduce stone formation in enteric hyperoxaluria.


A diet reduced in fat and oxalate can be beneficial in reducing stone formation.


Alkaline citrates and sodium bicarbonate can be used if hypocitraturia is present.


Allopurinol is first-line treatment of hyperuricosuria.


Febuxostat is second-line treatment of hyperuricosuria.


Avoid excessive intake of animal protein in hyperuricosuria.


Restricted intake of salt is beneficial if there is high urinary sodium excretion.



Strength rating

Prescribe thiazide or alkaline citrates or both in case of hypercalciuria*.


Advise oxalate restriction if hyperoxaluria is present.


Offer alkaline citrates in enteric hyperoxaluria.


Offer calcium supplement in enteric hyperoxaluria.


Advise reduced dietary fat and oxalate in enteric hyperoxaluria.


Prescribe alkaline citrates or sodium bicarbonate in case of hypocitraturia.


Prescribe allopurinol in case of hyperuricosuria.


Offer febuxostat as second-line treatment of hyperuricosuria.


Avoid excessive intake of animal protein in hyperuricosuria.


Advise restricted intake of salt if there is high urinary sodium excretion.


* Patients on hydrochlorothiazides should be advised to get their skin checked on a regular basis as they have a higher risk of developing a NMSC and some forms of melanoma. In patients with history of skin cancer the indication for the intake of hydrochlorothiazides should be thoroughly reviewed [661-663].

4.5. Calcium phosphate stones

Some calcium phosphate stone formers are at high risk of recurrence. Further information on identifying high-risk patients is provided in section 3.1.3.

Calcium phosphate mainly appears in two completely different minerals: carbonate apatite and brushite. Carbonate apatite crystallisation occurs at a pH > 6.8 and may be associated with infection. Brushite crystallises at an optimum pH of 6.5-6.8 at high urinary concentrations of calcium (> 8 mmol/day) and phosphate (> 35 mmol/day). Its occurrence is not related to UTI. Possible causes of calcium phosphate stones include HPT, RTA and UTI; each of which requires different therapy.

4.5.1. Diagnosis

Diagnosis requires blood analysis for: creatinine, sodium, potassium, chloride, ionised calcium (or total calcium + albumin), phosphate, and PTH (in the case of increased calcium levels). Urinalysis includes measurement of: volume, urine pH profile, specific weight, calcium, phosphate and citrate.

4.5.2. Interpretation of results and aetiology

General preventative measures are recommended for fluid intake and diet. The diagnostic and therapeutic algorithm for calcium phosphate stones is shown in Figure 4.4.

Figure 4.4: Diagnostic and therapeutic algorithm for calcium phosphate stonesHPT = hyperparathyroidism; RTA = renal tubular acidosis; UTI = urinary tract infection.
* Patients on hydrochlorothiazides should be advised to get their skin checked on a regular basis as they have a higher risk of developing a NMSC and some forms of melanoma. In patients with history of skin cancer the indication for the intake of hydrochlorothiazides should be thoroughly reviewed [661-663].

4.5.3. Pharmacological therapy

Hyperparathyroidism and RTA are common causes of calcium phosphate stone formation. Most patients with primary HPT require surgery. Renal tubular acidosis can be corrected pharmacologically including with bicarbonate or alkaline citrate therapy. If primary HPT and RTA have been excluded, pharmacotherapy for calcium phosphate calculi depends on effective reduction of urinary calcium levels using thiazides. For infection-associated calcium phosphate stones, it is important to consider the guidance given for infection stones.

4.5.4. Summary of evidence and recommendation for the management of calcium phosphate stones

Summary of evidence


Thiazide is beneficial in case of hypercalciuria.



Strength rating

Prescribe thiazide in case of hypercalciuria.


4.6. Disorders and diseases related to calcium stones

4.6.1. Hyperparathyroidism

Primary HPT is responsible for an estimated 5% of all calcium stone formation. Renal stones occur in approximately 20% of patients with primary HPT. Elevated levels of PTH significantly increase calcium turnover, leading to hypercalcaemia and hypercalciuria and bone disease. Serum calcium may be mildly elevated and serum PTH may be within the upper normal limits and, therefore, repeated measurements may be needed; preferably with the patient fasting. Stones of HPT patients may contain both calcium oxalate and calcium phosphate. Nephrocalcinosis and CKD may also occur.

If HPT is suspected, neck exploration should be performed to confirm the diagnosis. If surgery is contraindicated, primary HPT can be treated with cinacalcet.

4.6.2. Granulomatous diseases 675

Granulomatous diseases, such as sarcoidosis, may be complicated by hypercalcaemia and hypercalciuria secondary to increased calcitriol production. The latter is independent of PTH control, leading to increased calcium absorption in the gastrointestinal tract and suppression of PTH. Treatment focuses on the activity of the granulomatous diseases and may require steroids, hydroxychloroquine or ketoconazole. Treatment should be reserved for a specialist.

4.6.3. Primary hyperoxaluria 646

Patients with primary hyperoxaluria (PH) should be referred to specialised centres, as successful management requires an experienced interdisciplinary team. The main therapeutic aim is to reduce endogenous oxalate production, which is increased in patients with PH. In approximately one-third of patients with PH type I, pyridoxine therapy normalises or significantly reduces urinary oxalate excretion. The goal of adequate urine dilution is achieved by adjusting fluid intake to 3.5-4.0 L/day in adults (children 1.5 L/m2 body surface area) and following a circadian drinking regimen.

Therapeutic options for preventing calcium oxalate crystallisation include hyperdiuresis, alkaline citrates, magnesium and Lumasiran, an RNAi agent, which is a new treatment for reducing the synthesis of oxalate of PH type 1 [676].

Treatment regimens are:

  • pyridoxine in PH type I: 5-20 mg/kg/day according to urinary oxalate excretion and patient tolerance;
  • alkaline citrate: 9-12 g/day in adults, 0.1-0.15 mq/kg/day in children;
  • magnesium: 200-400 mg/day (no magnesium in the case of renal insufficiency).
  • Lumasiran: Subcutaneous injection with dose and timing adjusted according to body weight and duration of treatment: Initial Dose: Bodyweight < 10 kg: 6 mg/kg; Bodyweight 10-20 kg: 6 mg/kg; Bodyweight > 20 kg: 3 mg/kg; once per month for 3 months subcutaneous injection. Maintenance starting one month after initial doses: Bodyweight < 10 kg: 3 mg/kg 1-mal monthly; Bodyweight 10-20 kg: 6 mg/kg every 3 months, Bodyweight > 20 kg: 3 mg/kg. Summary of evidence and recommendation for the management of primary hyperoxaluria

Summary of evidence


Pyridoxine can reduce the urinary oxalate excretion in primary hyperoxaluria type 1.


Lumasiran can reduce the urinary oxalate excretion in primary hyperoxaluria type 1.



Strength rating

Prescribe pyridoxine for primary hyperoxaluria type 1.


4.6.4. Enteric hyperoxaluria [615, 620, 677-679]

Enteric hyperoxaluria is a particularly problematic condition in patients with intestinal malabsorption of fat. This abnormality is associated with a high risk of stone formation and is seen after intestinal resection and malabsorptive bariatric surgery, as well as in Crohn’s disease and pancreas insufficiency. In addition to hyperoxaluria, these patients usually present with hypocitraturia due to loss of alkali. Urine pH is usually low, as are urinary calcium and urine volume. All these abnormalities contribute to high levels of supersaturation with calcium oxalate, crystalluria, stone formation, and less frequently to nephrocalcinosis and CKD. Specific preventive measures are:

  • restricted intake of oxalate-rich foods [615];
  • restricted fat intake [615];
  • calcium supplementation at meal times to enable calcium oxalate complex formation in the intestine [620,677-679];
  • sufficient fluid intake to balance intestinal loss of water caused by diarrhoea;
  • alkaline citrates to raise urinary pH and citrate.

Summary of evidence


Alkaline citrates can be beneficial to replace citrate loss and raise urine pH.


Calcium supplements with meals enable calcium oxalate complex formation in the intestine.


Reduction in dietary fat and oxalate can be beneficial in intestinal malabsorption.



Strength rating

Prescribe alkaline citrates for enteric hyperoxaluria.


Advise patients to take calcium supplements with meals.


Advise patients to follow a diet with a low fat and oxalate content.


4.6.5. Renal tubular acidosis [597,636,680,681]

Renal tubular acidosis is caused by severe impairment of proton or bicarbonate handling along the nephron. Kidney stone formation most probably occurs in patients with distal RTA type I. Figure 4.5 outlines the diagnosis of RTA. Table 4.7 shows acquired and inherited causes of RTA.

Figure 4.5: Diagnosis of renal tubular acidosis

BGA = blood gas analysis; RTA = renal tubular acidosis.** An alternative ammonium chloride loading test using NH4Cl load with 0.05 g/kg body weight over three days might provide similar results and may be better tolerated by the patient [682]. A second alternative in these cases could be the furosemide/fludrocortisone acidification test [683].

Renal tubular acidosis can be acquired or inherited. Reasons for acquired RTA can be chronic obstructive uropathy, recurrent pyelonephritis, acute tubular necrosis, renal transplantation, analgesic nephropathy, sarcoidosis, Sjögren syndrome and other autoimmune diseases, medullary sponge kidney, liver cirrhosis, sickle cell anaemia, idiopathic hypercalciuria, and primary parathyroidism; it may also be drug-induced (e.g., amphotericin B, foscarnet, lithium, zonisamide and other carbonic anhydrase inhibitors).

Table 4.7: Inherited causes of renal tubular acidosis

Type - inheritance

Gene/gene product/function


Autosomal dominant

SLC4A1/AE1/Cl-bicarbonate exchanger

Hypercalciuria, hypokalaemia, rickets/osteomalacia

Autosomal recessive with hearing loss

ATP6V1B1/B1 sub-unit of vacuolar H-ATPase/proton secretion

Hypercalciuria, hypokalaemia,


Autosomal recessive

ATP6V0A4/A4 sub-unit of vacuolar H-ATPase/proton secretion

Hypercalciuria, hypokalaemia,


More rarely biallelic causative variants in FOXI1 and WDR72 genes have also been identified. The main therapeutic aim of RTA treatment is restoring a normal acid-base equilibrium. Despite the alkaline pH of urine in RTA, alkalinisation using alkaline citrates or sodium bicarbonate is important for normalising the metabolic changes (intracellular acidosis) responsible for stone formation (Table 4.8) and bone demineralisation. The alkali load reduces tubular re-absorption of citrate, which in turn normalises citrate excretion. Therapeutic success can be monitored by venous blood gas analysis (base excess: ± 2.0 mmol/L) in complete RTA. If excessive calcium excretion (> 8 mmol/day) persists after re-establishing acid-base equilibrium, thiazides may lower urinary calcium excretion.

Table 4.8: Pharmacological treatment of renal tubular acidosis

Biochemical risk factor

Indication for pharmacological




Calcium excretion > 8 mmol/day


- in adults: 25 mg/day initially, up to 50 mg/day

- in children: 0.5-1 mg/kg/day

Alternatives in adults:

Chlorthalidone 25 mg/day

Indapamide 2.5 mg/day

Inadequate urine pH

Citrate excretion

male < 1.7 mmol/day,

female < 1.9 mmol/day

Alkaline citrate, 9-12 g/day divided in three doses


Sodium bicarbonate, 1.5 g, three times daily

* Patients on hydrochlorothiazides should be advised to get their skin checked on a regular basis as they havea higher risk of developing a NMSC and some forms of melanoma. In patients with history of skin cancer the indication for the intake of hydrochlorothiazides should be thoroughly reviewed [661-663] Summary of evidence and recommendations for the management of tubular acidosis

Summary of evidence


Alkaline citrates can be beneficial in distal renal tubular acidosis to correct the intracellular acidosis.


Thiazide and alkaline citrates are beneficial for hypercalciuria.



Strength rating

Prescribe alkaline citrates for distal renal tubular acidosis.


Prescribe thiazide and alkaline citrates for hypercalciuria.


4.6.6. Nephrocalcinosis 684

Nephrocalcinosis (NC) refers to increased calcium crystal deposition within the renal cortex or medulla and occurs alone or in combination with renal stones. There are various metabolic causes. The main causes are: HPT, primary and enteric hyperoxalurias, genetic and acquired RTA, medullary sponge kidney, vitamin D metabolic disorders, sarcoidosis, idiopathic hypercalciuria and hypocitraturia, and genetic disorders, including Dent’s disease, Bartter’s syndrome. The many causes of NC mean there is no single standard therapy. Therapeutic attention must focus on the underlying metabolic or genetic disease, on the frequent association with CKD while minimising the biochemical risk factors. Diagnosis

Diagnosis requires the following blood analysis: PTH (in the case of increased calcium levels), vitamin D and metabolites, vitamin A, sodium, potassium, magnesium, chloride, and bicarbonate. Urinalysis should investigate urine pH profile at different times of the day daily urine volume, specific weight of urine, and levels of calcium, oxalate, phosphate, uric acid, magnesium, and citrate [585].

4.7. Uric acid and ammonium urate stones

All uric acid and ammonium urate stone formers are considered to be at high risk of recurrence [27]. Uric acid nephrolithiasis is responsible for approximately 10% of renal stones [685] and associated with hyperuricosuria or low urinary pH. Hyperuricosuria may be a result of dietary excess, endogenous overproduction (enzyme defects), myeloproliferative disorders, chemotherapy drugs, gout or catabolism [582]. Low urinary pH may be caused by decreased urinary ammonium excretion (insulin resistance or gout), increased endogenous acid production (insulin resistance, metabolic syndrome, or exercise-induced lactic acidosis), increased acid intake (high animal protein intake), or increased base loss (diarrhoea) [582].

Ammonium urate stones are extremely rare, comprising < 1% of all types of urinary stones. They are associated with UTI, malabsorption (inflammatory bowel disease and ileostomy diversion or laxative abuse), phosphate deficiency, hypokalemia and malnutrition. Suggestions on uric acid and ammonium urate nephrolithiasis are based on level 3 and 4 evidence. Chronic kidney disease is frequently observed.

4.7.1. Diagnosis

Figure 4.6 shows the diagnostic algorithm for uric acid stones and figure 4.7 shows the therapeutic algorithm for uric acid and ammonium urate stones. Blood analysis requires measurement of creatinine, potassium, and uric acid levels. Urinalysis requires measurement of urine volume, urine pH profile, specific weight of urine, and uric acid level. Urine culture is needed in the case of ammonium urate stones.

4.7.2. Interpretation of results

Uric acid and ammonium urate stones form under completely different biochemical conditions. Low urine pH promotes uric acid crystallisation.

Hyperuricosuria is defined as uric acid excretion > 4 mmol/day and day and > 5 mmol/day in adult females and males, respectively or > 0.12 mmol/kg/day in children. Hyperuricaemia may be present, but there is only weak evidence for its association with stone formation [686].

Hyperuricosuric calcium oxalate stone formation can be distinguished from uric acid stone formation by urinary pH, which is usually > 5.5 in calcium oxalate stone formation and < 5.5 in uric acid stone formation and occasional absence of hyperuricosuria in patients with pure uric acid stones [687,688]. Ammonium urate crystals form in urine at pH > 6.5, high uric acid concentration when ammonium is present [689,690].

4.7.3. Specific treatment

General preventive measures are recommended for fluid intake and diet. Hyperuricosuric stone formers benefit from purine reduction in their daily diet. Figure 4.6 describes pharmacological treatment [27,685,687-697]. For uric acid stones, allopurinol may change the stone composition distribution in patients with gout to a pattern similar to that in stone formers without gout [698].

Figure 4.6: Diagnostic algorithm for uric acid stonesADPKD = autosomal dominant polycystic kidney disease; G6P = glucose-6 phosphate dehydrogenase; HGPT = hypoxanthine guanine phosphorybosyl transferase; PRPS = phosphoribosyl-pyrophosphate synthetase superactivity; XO = xanthine oxidase. 

Figure 4.7: Therapeutic algorithm for uric acid- and ammonium urate stones1 d: day.
2 tid: three times a day.
3 A higher pH may lead to calcium phosphate stone formation.
4 In patients with high uric acid excretion, allopurinol may be helpful.

4.7.4. Summary of evidence and recommendations for the management of uric acid- and ammonium urate stones

Summary of evidence


Alkaline citrates can be beneficial to alkalinise the urine in uric acid stone formers.


Allopurinol can be beneficial in hyperuricosuric urate stone formers.



Strength rating

Prescribe alkaline citrates to alkalinise the urine in uric acid stone formers.


Prescribe allopurinol in hyperuricosuric urate stone formers.


4.8. Struvite and infection stones

All infection-stone formers are deemed at high risk of recurrence. Struvite stones represent 2-15% of the stones sent for analysis. Stones that contain struvite may originate de novo or grow on pre-existing stones, which are infected with urea-splitting bacteria [699]. There are several factors predisposing patients to struvite stone formation (Table 4.9) [700]. A number of studies have reported that urinary metabolic alterations can be disclosed in 36-81% of patients with mixed struvite stones [701-706].

4.8.1. Diagnosis

Blood analysis requires measurement of creatinine, and urinalysis requires repeat urine pH measurements and urine culture. In cases of mixed struvite stones the search of metabolic abnormalities in 24 hour urine after stone removal and infection control is suggested.

4.8.2. Interpretation

Infection stones contain the following minerals: struvite and/or carbonate apatite and/or ammonium urate. Urine culture typically provides evidence for urease-producing bacteria, which increase ammonia ions and develop alkaline urine (Table 4.10). Carbonate apatite starts to crystallise at a urine pH level of 6.8. Struvite only precipitates at pH > 7.2 [707,708]. A mixed struvite stones, i.e. containing a high percentage of calcium oxalate and carbonate apatite, suggests the over infection of a “metabolic” calcium oxalate or calcium phosphate stone [706]. Proteus mirabilis accounts for more than half of all urease-positive UTIs [709,710].

4.8.3. Specific treatment

General preventive measures are recommended for fluid intake and diet. Specific measures include complete surgical stone removal [700], short- or long-term antibiotic treatment [711], urinary acidification using methionine [642] or ammonium chloride [712], and advice to restrict intake of urease [713,714]. For persistent infections/colonisation, acetohydroxamic acid may be an option [713,714] (Figure 4.8); however, it is not licensed/available in all European countries.

Eradication of infection after complete stone removal is desirable. The evidence regarding the duration of post-operative antibiotic administration is inconclusive.

Summary of evidence


Removing the stone material as completely as possible with surgery can reduce ongoing infection.


Antibiotics are beneficial after complete stone removal.


Ammonium chloride, 1 g, two or three times daily, can ensure urinary acidification to prevent recurrent infection.


Methionine, 200-500 mg, one to three times daily, can be used as an alternative to ammonium chloride, to ensure urinary acidification.


Treatment of underlying metabolic abnormalities reduces recurrence of mixed struvite stones.


Urease inhibitors in case of severe infection are occasionally used (if licensed).



Strength rating

Surgically remove the stone material as completely as possible.


Prescribe antibiotics in case of persistent bacteriuria.


Prescribe ammonium chloride, 1 g, two or three times daily to ensure urinary acidification.


Prescribe methionine, 200-500 mg, one to three times daily, as an alternative, to ensure urinary acidification.


Table 4.9: Factors predisposing to struvite stone formation

Neurogenic bladder

Spinal cord injury/paralysis

Continent urinary diversion

Ileal conduit

Foreign body

Stone disease

Indwelling urinary catheter

Urethral stricture

Benign prostatic hyperplasia

Bladder diverticulum


Calyceal diverticulum

UPJ obstruction

Table 4.10: Most important species of urease-producing bacteria

Obligate urease-producing bacteria (> 98%)

Proteus spp.

Providencia rettgeri

Morganella morganii

Corynebacterium urealyticum

Ureaplasma urealyticum

Facultative urease-producing bacteria

Enterobacter gergoviae

Klebsiella spp.

Providencia stuartii

Serratia marcescens

Staphylococcus spp.

CAUTION: 0-5% of Escherichia coli, Enterococcus spp. and Pseudomonas aeruginosa strains may produce urease.

Figure 4.8: Diagnostic and therapeutic algorithm for infection stones.1 Discussed with uric acid stones.
2 Acetohydroxamic acid.
* When nationally available.
bid = twice a day; tid = three times a day; AHA = acetohydroxamic acid.

4.9. Cystine stones

Cystine stones account for 1-2% of all urinary stones in adults and 6-8% of the stones reported in paediatric studies [37,715]. All cystine stone formers are deemed at high risk of recurrence and CKD [716,717].

4.9.1. Diagnosis

Blood analysis includes measurement of creatinine, and urinalysis includes measurement of urine volume, pH profile, specific weight, and cystine. Since the disease may be asymptomatic, siblings of cystinuric patients should be investigated for cystinuria [718].


  • Cystine is poorly soluble in urine and crystallises spontaneously within the physiological urinary pH range.
  • Cystine solubility depends strongly on urine pH: at pH 6.0, the limit of solubility is 1.33 mmol/L.
  • Routine analysis of cystine is not suitable for therapeutic monitoring.
  • Regardless of phenotype or genotype of the cystinuric patient, the clinical manifestations are the same [719].
  • There is no role for genotyping patients in the routine management of cystinuria [720,721].
  • Reductive therapy targets the disulphide binding in the cystine molecule. For therapy monitoring, it is important to differentiate between cystine, cysteine and drug-cysteine complexes. However, available methods to monitor cystinuria treatment are cumbersome [722,723], or inaccurate including high-performance liquid chromatography (HPLC) which may be able to differentiate between the different complexes formed by therapy [69].
  • Quantitative 24-hour urinary cystine excretion confirms the diagnosis in the absence of stone analysis.
  • Levels above 0.125 mmol/day (30 mg/day) are considered abnormal [724,725].

4.9.2. Specific treatment

General preventative measures for fluid intake and diet are recommended. A diet low in methionine may theoretically reduce urinary excretion of cystine; however, patients are unlikely to comply sufficiently with such a diet. A restricted intake of sodium is more easily achieved and is more effective in reducing urinary cystine. Patients are usually advised to avoid sodium consumption > 2 g/day (5 g NaCl) [726]. A high level of diuresis is of fundamental importance, aiming for a 24-hour urine volume of > 3 L [719,726-728]. A considerable fluid intake evenly distributed throughout the day is necessary. Pharmacological treatment of cystine stones

The main therapeutic option for avoiding cystine crystallisation is to maintain urine pH > 7.5, to improve cysteine solubility and ensure appropriate hydration with a minimum of 3.5 L/day in adults, or 1.5 L/m2 body surface area in children [719,726-728]. Home monitoring of the urine pH is suggested because of the possibility to self-adjust alkaline treatment keeping the urine pH in range [69].

Free cystine concentration can be decreased by reductive substances, which act by splitting the disulphide binding of cystine.

Tiopronin is currently the best choice for cystine reduction. However, side effects often lead to treatment termination, for example when nephrotic syndrome develops or when there is poor compliance, especially with long-term use. After carefully considering the risk of early tachyphylaxis, put into place a dose-escape phenomenon for long-term use, and recurrence risk. Tiopronin is recommended at cystine levels > 3.0 mmol/day (720 mg/day) or in the case of recurring stone formation, notwithstanding other preventive measures [719,726-728]. Spot measurement of urine protein should be performed at baseline and during follow-up.

Figure 4.9: Metabolic management of cystine stones 

4.9.3. Summary of evidence and recommendations for the management of cystine stones

Summary of evidence


Increasing fluid intake so that 24-hour urine volume exceeds 3 L is used to dilute the cystine.


Alkaline citrates 3-10 mmol two or three times daily can be used to achieve pH > 7.5.


Tiopronin, 250-2,000 mg/day can be used to reduce stone formation in patients with cystine excretion, > 3 mmol/day, or when other measures are insufficient.



Strength rating

Therapeutic measures

Urine dilution

Advise patients to increase their fluid intake so that 24-hour urine volume exceeds 3 L.



Prescribe potassium citrate 3-10 mmol two or three times daily, to achieve pH > 7.5 for patients with cystine excretion < 3 mmol/day.


Complex formation with cystine

For patients with cystine excretion, > 3 mmol/day, or when other measures are insufficient: prescribe in addition to other measures tiopronin, 250-2,000 mg/day.


4.10.2,8-Dihydroxyandenine stones and xanthine stones

All 2,8-Dihydroxyadenine and xanthine stone formers are considered to be at high risk of recurrence. Both stone types are rare. Diagnosis and specific prevention are similar to those for uric acid stones [27].,8-Dihydroxyadenine stones

A genetically determined defect of adenine phosphoribosyl transferase causes high urinary excretion of poorly soluble 2,8-Dihydroxyadenine [730]. High-dose allopurinol or febuxostat are important options but should be given with regular monitoring [731].

4.10.2. Xanthine stones

Patients who form xanthine stones usually show decreased levels of serum uric acid. There is no available pharmacological intervention.

4.10.3. Fluid intake and diet

Recommendations for general preventive measures apply. Pharmacological intervention is difficult; therefore, high fluid intake ensures optimal specific weight levels of urine < 1.010 (urine specific gravity). A purine-reduced diet decreases the risk of spontaneous crystallisation in urine.

4.11. Drug-induced stones

Drug stones are induced by pharmacological treatment [627,732] (Table 4.10). Two types exist:

  • stones formed by crystallised compounds of the drug;
  • stones formed due to unfavourable changes in urine composition under drug therapy.

Table 4.11: Compounds that cause drug stones

Active compounds crystallising in urine

Substances impairing urine composition






Indinavir and other HIV-protease inhibitors

Magnesium trisilicate





Aluminium magnesium hydroxide

Ascorbic acid







Vitamin D



4.12. Matrix Stones

Pure matrix stones are extremely rare with less than 70 cases described in the literature. They are more prevalent in females. The main risk factors are recurrent UTIs, especially due to P. mirabilis or E. coli, previous surgery for stone disease, chronic renal failure, and haemodialysis. Complete endourological removal, frequently via the percutaneous approach, is critical. Given the rarity of matrix calculi a specific prophylactic regimen to minimise recurrence cannot be recommended. Eliminating infections and prophylactic use of antibiotics are most commonly proposed [733].

4.13. Unknown stone composition  [20]

An accurate medical history is the first step towards identifying risk factors as summarised in sections 3.1.3 and 4.13.1 and Fig. 4.1.

Diagnostic imaging begins with US examination of both kidneys to establish whether the patient is stone free. Stone detection by US should be followed by KUB and unenhanced multislice CT in adults to differentiate between calcium-containing and non-calcium stones.

Blood analysis demonstrates severe metabolic and organic disorders, such as renal insufficiency, HPT or other hypercalcaemic states and hyperuricaemia. In children, hyper with low GFR oxalaemia should additionally be screened for.

Urinalysis is performed routinely with a dipstick test as described above. Urine culture is required if there are signs of infection. Urine pH < 5.5 in 24-hr urine collection indicates hyper acidic urine, which could promote uric acid crystallisation. Urine pH > 6.2 in 24-hr urine collection may indicate RTA, if UTI is excluded [679,681].

Microscopy of urinary sediment can help to discover rare stone types because crystals of 2,8-Dihydroxyadenine, cystine and xanthine are pathognomonic for the corresponding disease. In cases in which the presence of cystine is doubtful, a cyanide nitroprusside colorimetric qualitative test can be used to detect the presence of cystine in urine, with a sensitivity of 72% and specificity of 95%. False-positive results are possible in patients with Fanconi’s syndrome or homocystinuria, or in those taking various drugs, including ampicillin or sulfa-containing medication [734,735].

Following this programme, the most probable stone type can be assumed, and specific patient evaluation can follow. Further metabolic investigations will depend on the presence of risk factors (see section 3.1.3) and on the results of previous investigations. However, if any expulsed stone material is available, it should be analysed by diagnostic confirmation or correction.

4.13.1. Recommendations for investigations for the assessment of patients with stones of unknown composition [21,27,68,627]


Strength rating


Rationale for investigation

Take a medical history

• Stone history (former stone events, family history)

• Dietary habits

• Medication chart


Perform diagnostic imaging

• Ultrasound in the case of a suspected stone

• Un-enhanced helical computed tomography

• Determination of Hounsfield units provides

• Information about the possible stone composition


Perform a blood analysis

• Creatinine

• Calcium (ionised calcium or total calcium + albumin)

• Uric acid


Perform a urinalysis

• Urine pH profile (measurement after each voiding, minimum four times daily)

• Dipstick test: leukocytes, erythrocytes, nitrites, protein, urine pH, specific weight

• Urine cultures

• Microscopy of urinary sediment (morning urine)

• Cyanide nitroprusside test (cystine exclusion)

Further examinations depend on the results of the investigations listed above.